HIGH SPRINGS, FL--(Marketwire - 04/05/11) - CTD Holdings, Inc. (Pinksheets:CTDH) (OTC.BB:CTDH), an international leader in the manufacturing and marketing of cyclodextrin-based compounds, has filed its Annual Report on Form 10K with the SEC for the fiscal year ended Dec. 31st, 2010.
In 2010 the company grew its annual revenues to a record $ 804,000, representing a 33% increase over the previous year. Sales increased steadily during the year, with the fourth quarter achieving the highest ever quarterly revenues of $270,000. As a result of investing its strong positive cash flow, the total asset value of the company increased 49% as compared to 2009.
The company continued to actively manage its expenses, which were lower in 2010 as compared to 2009. This was accomplished in spite of staffing the new NanoSonic Products, Inc. company and hiring of Dr. Jeffrey Tate as its President & CEO. CTD Holdings Inc. reduced its net loss per share by 80% to $ 38,567 in 2010 from $ 193,127 in 2009.
"It is this dynamic and the company's ability to shelter profits with $ 630,000 of tax loss carryovers, good through 2017, that makes us extremely bullish about the company's future growth," says company Chairman & CEO Mr. C.E. "Rick" Strattan.
The record shows that 2010 has proven to be a pivotal year for the implementation of the CTD Holdings, Inc. growth strategy and the results are just beginning to be realized. With the addition of Dr. Tate to head the new NanoSonic Products, Inc. division, the company has brought in a seasoned executive with the technical and regulatory expertise to implement the proprietary manufacturing technology for large-scale production of the Aquaplex® brand cyclodextrin complexes.
In 2010 the company purchased a new manufacturing facility in Alachua, FL adjacent to the University of Florida biotechnology complex. The building is currently being outfitted with 21st century manufacturing equipment and is scheduled to be fully operational in the third quarter of 2011. This will mark another important milestone in the overall growth plan.
"The universally understandable business tactic of building proprietary manufacturing capacity to meet the growing demands for Aquaplex® water-soluble ingredients is being implemented," finished Mr. Strattan.
If you would like more information about this topic or would like to schedule an interview with Dr. Tate, please contact our Director of Corporate Communication, David Corner at 386-454-0887 or send an email to email@example.com.
Safe Harbor Statement: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc. accepts no specific responsibility for updating such statements.